Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biomarin Pharmaceuticals (BMRN)

Biomarin Pharmaceuticals (BMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,310,665
  • Shares Outstanding, K 192,114
  • Annual Sales, $ 2,854 M
  • Annual Income, $ 426,860 K
  • EBIT $ 596 M
  • EBITDA $ 685 M
  • 60-Month Beta 0.26
  • Price/Sales 4.08
  • Price/Cash Flow 19.54
  • Price/Book 2.01

Options Overview Details

View History
  • Implied Volatility 51.40% (-2.92%)
  • Historical Volatility 27.92%
  • IV Percentile 98%
  • IV Rank 85.39%
  • IV High 55.63% on 04/10/25
  • IV Low 26.64% on 03/24/25
  • Expected Move (DTE 25) 6.21 (9.68%)
  • Put/Call Vol Ratio 0.14
  • Today's Volume 1,169
  • Volume Avg (30-Day) 1,136
  • Put/Call OI Ratio 0.59
  • Today's Open Interest 36,773
  • Open Int (30-Day) 30,502
  • Expected Range 57.88 to 70.29

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 24 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.07
  • Number of Estimates 4
  • High Estimate 0.14
  • Low Estimate -0.06
  • Prior Year 0.72
  • Growth Rate Est. (year over year) -90.28%

Price Performance

See More
Period Period Low Period High Performance
1-Month
55.28 +15.92%
on 01/30/26
64.25 -0.26%
on 02/20/26
+7.77 (+13.80%)
since 01/20/26
3-Month
50.90 +25.89%
on 12/15/25
64.25 -0.26%
on 02/20/26
+11.60 (+22.10%)
since 11/20/25
52-Week
50.76 +26.24%
on 11/07/25
73.51 -12.83%
on 03/07/25
-4.65 (-6.77%)
since 02/20/25

Most Recent Stories

More News
BioMarin Pharmaceutical Earnings: What To Look For From BMRN

BioMarin Pharmaceutical Earnings: What To Look For From BMRN

BMRN : 64.08 (+1.04%)
BioMarin to Host Fourth Quarter and Full-Year 2025 Financial Results Conference Call and Webcast on Monday, February 23, 2026, at 4:30pm ET

SAN RAFAEL, Calif. , Feb. 17, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a...

BMRN : 64.08 (+1.04%)
BioMarin Announces Closing of Private Offering of Senior Notes

SAN RAFAEL, Calif. , Feb. 12, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ("BioMarin") announced today that it closed its previously announced offering of $850 million of 5.500%...

BMRN : 64.08 (+1.04%)
BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility

SAN RAFAEL, Calif. , Jan. 29, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ("BioMarin") announced today that it priced its previously announced offering of $850 million of 5.500%...

BMRN : 64.08 (+1.04%)
BioMarin Announces Proposed Private Offering of Senior Notes and Syndication of New Senior Secured Term Loan Facility

SAN RAFAEL, Calif. , Jan. 26, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ("BioMarin") announced today that it intends to offer, subject to market and other conditions, $850...

BMRN : 64.08 (+1.04%)
BioMarin Appoints Arpit Davé Chief Digital and Information Officer

Mr. Davé Brings more than 20 Years of Experience in Creating Enterprise Value through Digital Transformation, Information Technology and Artificial Intelligence across the Biopharmaceutical Industry

BMRN : 64.08 (+1.04%)
1 of Wall Street’s Favorite Stock with Exciting Potential and 2 We Find Risky

1 of Wall Street’s Favorite Stock with Exciting Potential and 2 We Find Risky

APPN : 25.14 (+2.44%)
PVH : 72.17 (+3.59%)
BMRN : 64.08 (+1.04%)
BioMarin to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, at 11:15 am PT / 2:15 pm ET, in San Francisco, CA

SAN RAFAEL, Calif. , Jan. 8, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will present...

BMRN : 64.08 (+1.04%)
Veeva and BioMarin Form Long-Term Strategic Partnership

Partnership to help BioMarin increase speed and efficiency  in developing and commercializing innovative therapies

VEEV : 180.31 (-1.24%)
BMRN : 64.08 (+1.04%)
Amicus Therapeutics Investment Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amicus Therapeutics, Inc. - FOLD

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Amicus Therapeutics...

FOLD : 14.34 (-0.07%)
BMRN : 64.08 (+1.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

BioMarin Pharmaceutical Inc. focuses on the development and commercialization of treatments for serious life-threatening medical conditions, mostly for children. The company's portfolio comprises seven marketed products namely, Aldurazyme, Naglazyme, Kuvan a rare genetic enzyme deficiency disorder),...

See More

Key Turning Points

3rd Resistance Point 66.40
2nd Resistance Point 65.33
1st Resistance Point 64.70
Last Price 64.08
1st Support Level 63.00
2nd Support Level 61.93
3rd Support Level 61.30

See More

52-Week High 73.51
Fibonacci 61.8% 64.82
Last Price 64.08
Fibonacci 50% 62.14
Fibonacci 38.2% 59.45
52-Week Low 50.76

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar